Sacubitril/valsartan (97-103mg BID) demonstrated superiority to enalapril (20mg) in the reduction of cardiovascular death and hospitalization in heart failure patients with a reduced ejection fraction (HFrEF). 2 Hypotension eliminated some candidates during the runin phase. 2 Historical trials have also demonstrated a substantial decrease in systolic blood pressures (SBP) with dual angiotensin/neprilysin blockade compared with either class used alone. [3] [4] Specific subsets of patients who are initiated on sacubitril/valsartan during hospitalization may be unable tolerate the medication for continuation on discharge due to hypotension.
In our preliminary study, 50% of patients initiated on sacubitril/valsartan during hospitalization were prescribed therapy at discharge.
Hospitalized patients who tolerated sacubitril/valsartan initiation tended to have higher baseline SBP and LVEF with a lower SCr.
Due to concomitant vasoactive agents, systolic blood pressures should be interpreted with caution.
Although limited by a small sample size in this preliminary observation, we identified the most common reason for medication discontinuation was hypotension.
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